Five year follow up on FFR guided PCI for Stable CAD – What Did We Learn From FAME2?

In the final follow up of the FAME 2 study,  published in The New England Journal of Medicine, five year outcomes were reported comparing percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) to medical therapy alone. The hypothesis had suggested FFR guided PCI would be superior to medical therapy as initial treatment in patients with stable coronary artery disease. Continue reading

Discharging Patients Is Safe, the Next Day After Minimalist TAVR

In a recent study published in the Journal of the American College of Cardiology (JACC), it was found that patients undergoing uncomplicated TAVR have a safe next-day discharge (NDD) profile with no difference in 30-day mortality rate in comparison to an increased length of hospital stay. In addition, the study also highlighted better 1-year clinical outcomes in patients as compared to non-NDD group. Continue reading

Greater Cholesterol Variability Is a Predictor for Atheroma Progression

“The variation in cholesterol levels is associated with an increase in the percentage of atheroma volume and worse clinical outcomes,” says a new meta-analysis in the European Heart Journal. Continue reading

Coronary Sinus Reducer Implantation Improves Chronic Refractory Angina

A recent study published in the Journal of American College of Cardiology found that implantation of the coronary sinus Reducer is safe and is associated with a reduction of anginal symptoms and improvement of quality of life in patients with refractory angina who were not candidates for further revascularization. Continue reading

Management of Cardiogenic Shock

Dr. Naidu, Dr. Brikalis, and Dr. C. Michael Gibson Discuss

ORBITA Trial & Panel Discussion

Dr. Kirk Garratt, Dr. Ajay Kirtane and Dr. C. Michael Gibson Discuss

Management of Cardiogenic Shock Dr. Naidu, Dr. Brikalis, and Dr. C. Michael Gibson Discuss

ORBITA Trial & Panel Discussion Dr. Kirk Garratt, Dr. Ajay Kirtane and Dr. C. Michael Gibson Discuss

Pre-PCI Impella Device Improves Outcome in Acute MI complicated by Cardiogenic Shock (AMICS)

A non-randomized study published in the American Heart Journal showed increased survival rates in patients with Impella device being used as the first support strategy for patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) when invasive hemodynamic monitoring was used, and at centers with higher Impella implantation volume. Continue reading

Recent Trends of TAVR in France

In a recent study published in the Journal of the American College of Cardiology, the implementation of Transcatheter Aortic Valve Replacement (TAVR) was investigated in France.

Continue reading

EAGLES- A Randomized Clinical Trial Showing No Evidence of Smoking Cessation Treatments Association with MACE

EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a randomized clinical trial, published in the Journal of the American Medical Association, provides evidence that smoking cessation medications do not increase the risk of serious cardiovascular events in the general population of smokers. Continue reading

Video Augmented Information Delivery to Patients Undergoing Elective PCI Enhances Patient Awareness and Satisfaction

A new multi-center prospective randomized trial published in the American Heart Journal was able to show that a video presentation may be better at helping patients to understand the procedure and risks associated with percutaneous coronary intervention (PCI) compared to standard patient education pamphlets. Continue reading

Delayed Coronary Obstruction: a post-TAVR Complication

A recently published study in the Journal of American College of Cardiology  concluded that delayed coronary obstruction (DCO) occurring after transcatheter aortic valve replacement (TAVR) is an infrequent complication, associated with a high in-hospital mortality. Continue reading

High Sensitivity Troponin I and Stable Coronary Artery Disease

A recent study published in the Journal of American College of Cardiology found an association between elevated concentrations of high sensitivity troponin I (hsTnI) with increasing prevalence of coronary artery disease (CAD) in stable patients, who were suspected of coronary artery disease and underwent non-emergent coronary computed tomography angiography (CTA).

Continue reading

Tafamidis, A Real Hope for People with Transthyretin Cardiomyopathy?

On Thursday, March 29th, Pfizer announced positive topline results from ATTR-ACT trial of tafamidis in patients with transthyretin cardiomyopathy. According to Pfizer, “Tafamidis met its primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months. The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified”. Continue reading

Predictors of Device Related Thrombosis After Transcatheter Left Atrial Appendage Occlusion

In a recent study published in Circulation: Cardiovascular Interventions, Pracon et al. suggested that the incidence of device related thrombosis (DRT) among patients undergoing percutaneous left atrial appendage occlusion is related to patient  (history of thromboembolic events and lower left ventricular ejection fraction) and procedural (deep implantation and larger occluder size) characteristics.

Continue reading

Does Operator PCI Volume Influence Mortality?

The number of procedures performed by the operator of a Percutaneous Coronary Intervention (PCI) in the previous year has no impact on the 30-day mortality, according to a recent UK study published in the European Heart Journal Continue reading

Do Procedure and Coronary Lesion Characteristics Impact Clinical Outcomes in Atrial Fibrillation Patients Undergoing PCI?

According to a post-hoc analysis of the PIONEER AF-PCI trial that was recently published in the Journal of American College of Cardiology,  there was no impact of complex coronary lesions, stent characteristics, or vascular approach on efficacy or safety outcomes among stented atrial fibrillation (AF) patients who received either rivaroxaban or Vitamin K Antagonists (VKA)-based dual or triple therapy. Continue reading

SWAP 4 trial: De-escalation of P2Y12 Inhibitors

In a recent article published in The Circulation, it has been found that the use of a loading dose while switching between P2Y12 inhibitors in patients with coronary artery disease is associated with mitigation of the reactivity of platelets. The study has also emphasized that timing of administration of loading dose has no impact on platelet reactivity.

Continue reading

Frailty and Conventional Risk Scores in Patients Undergoing TAVR

The usage of combined risk models of frailty and conventional risk scores significantly enhances prediction of one-year mortality in patients undergoing TAVR, according to a recent publication in the Journal of American College of Cardiology.

Continue reading